However, the above evidence seems to be less convincing than the evidence coming from the following investigations regarding the role of PDK1 in BC metastasis to support PDK1 as a potential targeted therapy in BC owing to the evidence that relatively delayed BC lesions are ultimately generated in a handful of PDK1-deficient tumorigenic cells [49], as well as the evidence that PDK1 harnesses migratory and oncogenic transforming behaviors rather than growing and proliferative phenotypes in PTEN-loss lymphocytes [51]. Here, PDK1 is linked to breast cancer.